3,100 Shares in Phibro Animal Health Co. (NASDAQ:PAHC) Acquired by nVerses Capital LLC

nVerses Capital LLC acquired a new position in shares of Phibro Animal Health Co. (NASDAQ:PAHC) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 3,100 shares of the company’s stock, valued at approximately $70,000.

A number of other institutional investors have also recently added to or reduced their stakes in PAHC. CWM LLC boosted its holdings in shares of Phibro Animal Health by 190.8% during the third quarter. CWM LLC now owns 6,363 shares of the company’s stock valued at $143,000 after acquiring an additional 4,175 shares during the period. SG Americas Securities LLC acquired a new position in Phibro Animal Health during the 3rd quarter valued at about $276,000. Sanctuary Advisors LLC bought a new position in Phibro Animal Health in the 2nd quarter worth about $481,000. Dana Investment Advisors Inc. increased its stake in shares of Phibro Animal Health by 17.2% in the second quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after purchasing an additional 75,546 shares during the period. Finally, Truist Financial Corp bought a new stake in shares of Phibro Animal Health during the second quarter valued at approximately $308,000. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health Stock Performance

Shares of NASDAQ PAHC opened at $23.65 on Tuesday. Phibro Animal Health Co. has a 1 year low of $9.40 and a 1 year high of $25.11. The firm has a market cap of $957.90 million, a P/E ratio of 73.91, a PEG ratio of 0.60 and a beta of 0.52. The stock has a fifty day moving average price of $21.26 and a two-hundred day moving average price of $18.41. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.64 and a current ratio of 2.94.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.07. Phibro Animal Health had a return on equity of 18.08% and a net margin of 0.24%. The business had revenue of $273.16 million during the quarter, compared to analysts’ expectations of $262.44 million. Research analysts forecast that Phibro Animal Health Co. will post 1.55 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 25th. Investors of record on Wednesday, September 4th were paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 2.03%. The ex-dividend date was Wednesday, September 4th. Phibro Animal Health’s dividend payout ratio is presently 150.00%.

Insider Buying and Selling

In related news, Director E Thomas Corcoran purchased 5,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were bought at an average price of $20.02 per share, with a total value of $100,100.00. Following the completion of the acquisition, the director now owns 25,000 shares of the company’s stock, valued at approximately $500,500. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 50.06% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Bank of America increased their price objective on Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a report on Friday, August 30th. JPMorgan Chase & Co. initiated coverage on Phibro Animal Health in a report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price target on the stock. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $15.00.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.